- Conditions
- IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN), IC-MPGN
- Interventions
- ADX-038 Dose Level 2, ADX-038 Dose Level 1
- Drug
- Lead sponsor
- ADARx Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 11
- States / cities
- Doral, Florida • Miami, Florida • Pembroke Pines, Florida + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 75
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Immunoglobulin A Nephropathy, Healthy Subjects
- Interventions
- Fish Oil
- Dietary Supplement
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Davis, California
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, IgAN, LN
- Interventions
- ALXN2050, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 10
- States / cities
- Huntsville, Alabama • Loma Linda, California • Northridge, California + 7 more
- Conditions
- IgA Nephropathy (IgAN), Immunoglobulin A Nephropathy (IgAN)
- Interventions
- atrasentan
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Interventions
- Povetacicept
- Drug
- Lead sponsor
- Alpine Immune Sciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Valencia, California + 14 more
- Conditions
- Immunoglobulin A (IgA) Nephropathy
- Interventions
- PS-002
- Genetic
- Lead sponsor
- Purespring Therapeutics Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Miami, Florida • Baltimore, Maryland
- Conditions
- Immunoglobulin A Nephropathy
- Interventions
- Sibeprenlimab 400 mg, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more
- Conditions
- Primary IgA Nephropathy
- Interventions
- Sefaxersen (RO7434656), Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 459 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Glendale, California • Los Angeles, California + 15 more
- Conditions
- Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis, Glomerular Disease, Glomerulonephritis, IGA, Glomerulopathy, Immunoglobulin Disease
- Interventions
- zigakibart
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Orlando, Florida • Iowa City, Iowa + 5 more
- Conditions
- Primary IgA Nephropathy
- Interventions
- Nefecon, Placebo oral capsule
- Drug
- Lead sponsor
- Calliditas Therapeutics AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 365 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 28 more
- Conditions
- Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy, Primary Membranous Nephropathy
- Interventions
- WAL0921, Placebo
- Drug
- Lead sponsor
- Walden Biosciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Denver, Colorado • Tamarac, Florida + 5 more
- Conditions
- Kidney Disease, Glomerulonephritis
- Interventions
- Mezagitamab
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- Northridge, California • Nampa, Idaho • Evanston, Illinois
- Conditions
- IgA Nephropathy, Proteinuria
- Interventions
- Acthar 80 unit injection
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- IgA Nephropathy
- Interventions
- BHV-1400
- Drug
- Lead sponsor
- Biohaven Therapeutics Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 14
- States / cities
- Farmington, Connecticut • Miami Lakes, Florida • Orlando, Florida + 9 more
- Conditions
- IgA Nephropathy
- Interventions
- Mycophenolate Mofetil (MMF), MMF Placebo, ACEi, FOS
- Drug
- Lead sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
- Other
- Eligibility
- 7 Years to 70 Years
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Immunoglobulin A Nephropathy (IgAN)
- Interventions
- Felzartamab, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 454 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 29
- States / cities
- Little Rock, Arkansas • Apple Valley, California • Carlsbad, California + 25 more
- Conditions
- IgA Nephropathy, Immunoglobulin A Nephropathy
- Interventions
- Atrasentan, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Oak Brook, Illinois + 3 more
- Conditions
- Immunoglobulin A Nephropathy (IgAN)
- Interventions
- ARGX-121, Placebo
- Biological
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- Miami, Florida • Houston, Texas • Manassas, Virginia
- Conditions
- Immunoglobulin A Nephropathy, IgAN
- Interventions
- Ravulizumab, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 584 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 39
- States / cities
- Alabaster, Alabama • Phoenix, Arizona • Los Angeles, California + 30 more
- Conditions
- Primary Immunoglobulin A Nephropathy (IgAN)
- Interventions
- iptacopan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 5
- States / cities
- Madera, California • Aurora, Colorado • Gainesville, Florida + 2 more
- Conditions
- Immunoglobulin A Nephropathy (IgAN)
- Interventions
- zigakibart
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Acworth, Georgia • Iowa City, Iowa + 1 more
- Conditions
- Kidney Disease
- Interventions
- Mezagitamab, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 347 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Surprise, Arizona + 35 more
- Conditions
- IgA Nephropathy
- Interventions
- Intravenous Rituximab, ACE/ARB, Omega-3 Fatty Acid Fish Oil Supplement
- Drug · Dietary Supplement
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 5
- States / cities
- San Francisco, California • Rochester, Minnesota • New York, New York + 2 more
- Conditions
- IgA Nephropathy, Immunoglobulin A Nephropathy
- Interventions
- Atrasentan, Placebo, Zigakibart
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Alhambra, California • Glendale, California + 18 more